AstraZeneca has selected Virginia as the site of its largest global manufacturing facility, marking a multi-billion dollar investment that cements the state’s position as a leader in pharmaceutical manufacturing and innovation.
The new site is part of AstraZeneca’s broader strategy to invest $50 billion into its U.S. operations by 2030. The facility will focus on advanced pharmaceutical production, supporting the company’s goal of reaching $80 billion in global revenue by the end of the decade.
“This investment reflects our commitment to innovation and to the patients who rely on our medicines,” said Pascal Soriot, CEO of AstraZeneca. “It also strengthens the U.S. supply chain and supports our long-term growth strategy. We are proud to partner with Governor Youngkin and the Commonwealth of Virginia on this historic project.”
The investment is expected to create hundreds of highly skilled jobs and introduce cutting-edge manufacturing capabilities to the region. Governor Glenn Youngkin welcomed the decision, calling it a milestone for Virginia’s economy. “This project will set the standard for pharmaceutical manufacturing and reinforce our role in strengthening the nation’s domestic supply chain,” he said.
Advanced manufacturing is one of Virginia’s core industries, and this announcement significantly boosts the state’s life sciences ecosystem. With strong infrastructure, a skilled workforce, and proximity to research institutions, Virginia is poised to become a central hub for global pharmaceutical production.
The project underscores both AstraZeneca’s confidence in the U.S. biopharmaceutical landscape and Virginia’s growing reputation as a destination for high-impact investment.
